Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab

摘要

PurposeTo evaluate the efficiency and possible complications of intravitreal dexamethasone (IVD) implant in diabetic macular edema (DME) resistant to treatment of three consecutive intravitreal ranibizumab (IVR) injections.MethodsFifty eyes of 38 patients were considered in this study. The best corrected visual acuity (BCVA), central macular thickness (CMT), and values of intraocular pressure (IOP) were examined preoperatively and postoperatively in the 1st, 2nd, 4th, and 6th months of IVD implantation.ResultsTwenty of the patients were women, and 18 of the patients were men. Mean age was 64.63?±?7.15 (52–83) years. Mean number of IVR injection before IVD implantation was 3.4?±?0.38. Mean BCVA (logMAR) was 0.874?±?0.398 before IVD implantation, 0.598?±?0.306 at the 1st month, 0.602?±?0.340 at the 2nd month, 0.708?±?0.359 at 4th month, and 0.800?±?0.370 at 6th month. Mean of CMT was 519.700?±?155.802?μm before IVD implantation, 274.000?±?73.112?μm at the 1st month, 307.98?±?87.869?μm at the 2nd month, 387.82?±?110.503?μm at 4th month, and 478.54?±?163.743?μm at 6th month. Improvements in BCVA and CMT were statistically significant (P?